2023
ERAS Protocol Options for Perioperative Pain Management of Substance Use Disorder in the Ambulatory Surgical Setting
Zwolinski N, Patel K, Vadivelu N, Kodumudi G, Kaye A. ERAS Protocol Options for Perioperative Pain Management of Substance Use Disorder in the Ambulatory Surgical Setting. Current Pain And Headache Reports 2023, 27: 65-79. PMID: 37079258, PMCID: PMC10116112, DOI: 10.1007/s11916-023-01108-3.Peer-Reviewed Original ResearchConceptsSubstance use disordersSubstance use disorder patientsAmbulatory patientsUse disordersDisorder patientsERAS protocolPerioperative pain managementAmbulatory surgery settingHospital quality metricsAmbulatory surgical settingAmbulatory surgery casesPerioperative protocolPain managementAdverse outcomesAmbulatory surgeryPharmacodynamic profileSurgery settingAmbulatory proceduresSurgery casesClinical dataEarly recoveryAbused substancesSurgical settingPatientsSubspecialty groups
2020
Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study
Zamarin D, Hamid O, Nayak-Kapoor A, Sahebjam S, Sznol M, Collaku A, Fox FE, Marshall MA, Hong DS. Mogamulizumab in Combination with Durvalumab or Tremelimumab in Patients with Advanced Solid Tumors: A Phase I Study. Clinical Cancer Research 2020, 26: 4531-4541. PMID: 32586937, PMCID: PMC8375360, DOI: 10.1158/1078-0432.ccr-20-0328.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, MonoclonalAntibodies, Monoclonal, HumanizedAntineoplastic Agents, ImmunologicalAntineoplastic Combined Chemotherapy ProtocolsDose-Response Relationship, DrugFemaleHumansLymphocyte DepletionMaleMiddle AgedNeoplasm StagingPancreatic NeoplasmsReceptors, CCR4T-Lymphocytes, RegulatoryYoung AdultConceptsAdvanced solid tumorsDose escalationSolid tumorsCohort expansionEffector regulatory T cellsC chemokine receptor 4Phase IDose-expansion cohortsAdvanced pancreatic cancerObjective response rateMajority of patientsRegulatory T cellsChemokine receptor 4Potent antitumor efficacyMogamulizumab treatmentCheckpoint inhibitorsDose expansionExpansion cohortIntratumoral TregsPrimary endpointClinical responseEscalation studyBaseline degreePharmacodynamic profilePancreatic cancerDevelopment of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies
Falchook G, Rosen S, LoRusso P, Watts J, Gupta S, Coombs CC, Talpaz M, Kurzrock R, Mita M, Cassaday R, Harb W, Peguero J, Smith DC, Piha-Paul SA, Szmulewitz R, Noel MS, Yeleswaram S, Liu P, Switzky J, Zhou G, Zheng F, Mehta A. Development of 2 Bromodomain and Extraterminal Inhibitors With Distinct Pharmacokinetic and Pharmacodynamic Profiles for the Treatment of Advanced Malignancies. Clinical Cancer Research 2020, 26: 1247-1257. PMID: 31527168, PMCID: PMC7528620, DOI: 10.1158/1078-0432.ccr-18-4071.Peer-Reviewed Original ResearchConceptsAdvanced malignanciesGrade treatment-related adverse eventsTreatment-related adverse eventsAdequate organ functionHigh interpatient variabilityFavorable PK profileOptimal dosing schemePrimary endpointAdverse eventsOral clearancePartial responseComplete responsePhase 1/2Terminal eliminationTolerability studyPatient populationPharmacodynamic profileInterpatient variabilityDosing schemesDistinct pharmacokineticsTherapeutic indexOrgan functionPK profilesExtraterminal (BET) inhibitorsTarget inhibition
2019
Safety and pharmacodynamics of anti‐CD2 monoclonal antibody treatment in cynomolgus macaques – an experimental study
Berglund E, Alonso‐Guallart P, Danton M, Sellberg F, Binder C, Fröbom R, Berglund D, Llore N, Sakai H, Iuga A, Ekanayake‐Alper D, Reimann K, Sachs D, Sykes M, Griesemer A. Safety and pharmacodynamics of anti‐CD2 monoclonal antibody treatment in cynomolgus macaques – an experimental study. Transplant International 2019, 33: 98-107. PMID: 31523849, PMCID: PMC7017722, DOI: 10.1111/tri.13524.Peer-Reviewed Original ResearchConceptsAnti-CD2 treatmentT cellsStudy drug-related adverse eventsCynomolgus macaquesDrug-related adverse eventsEarly immune reconstitutionMemory T cellsLymph node examinationTreat transplant rejectionNaive T cellsMonoclonal antibody treatmentSecondary lymphoid organsMixed lymphocyte reactionAnti-CD2 monoclonal antibodiesImmune reconstitutionMLR inhibitionMemory subsetsNode examinationAntibody treatmentPeripheral bloodCD2 expressionLymphocyte reactionSafety profilePharmacodynamic profileTransplant rejection
2018
Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial
Laffel LMB, Tamborlane WV, Yver A, Simons G, Wu J, Nock V, Hobson D, Hughan KS, Kaspers S, Marquard J. Pharmacokinetic and pharmacodynamic profile of the sodium‐glucose co‐transporter‐2 inhibitor empagliflozin in young people with Type 2 diabetes: a randomized trial. Diabetic Medicine 2018, 35: 1096-1104. PMID: 29655290, PMCID: PMC6099360, DOI: 10.1111/dme.13629.Peer-Reviewed Original ResearchConceptsType 2 diabetesG/24 hPharmacodynamic profileType 2Type 2 diabetes trialsSodium-glucose co-transporter-2 inhibitor empagliflozinMaximum observed plasma concentrationPlasma concentration-time curveSimilar exposure-response relationshipsDoses of empagliflozinSerious adverse eventsParallel-group studyUrinary glucose excretionSingle oral doseDrug-related eventsObserved plasma concentrationConcentration-time curveExposure-response relationshipAdjusted mean increaseAdverse eventsDiabetes (ACCORD) trialGlucose excretionInhibitor empagliflozinOral doseMean ageAzithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease
Tsuji BT, Fisher J, Boadi-Yeboah R, Holden PN, Sethi S, Pettigrew MM, Murphy TF. Azithromycin Pharmacodynamics against Persistent Haemophilus influenzae in Chronic Obstructive Pulmonary Disease. Antimicrobial Agents And Chemotherapy 2018, 62: 10.1128/aac.01995-17. PMID: 29180527, PMCID: PMC5786777, DOI: 10.1128/aac.01995-17.Peer-Reviewed Original ResearchConceptsChronic obstructive pulmonary disease patientsObstructive pulmonary disease patientsChronic obstructive pulmonary diseaseHollow-fiber infection modelStrains of NTHiPulmonary disease patientsObstructive pulmonary diseasePulmonary diseaseConcentration-dependent activityDisease patientsPharmacodynamic profilePharmacodynamic responseSame patientHaemophilus influenzaeInfection modelPatientsAzithromycinPersistent strainsDaysAirwayNTHiPharmacodynamicsInfluenzaeDiseaseHaemophilus
2017
Inhalation of Alcohol Vapor: Measurement and Implications
MacLean RR, Valentine GW, Jatlow PI, Sofuoglu M. Inhalation of Alcohol Vapor: Measurement and Implications. Alcohol Clinical And Experimental Research 2017, 41: 238-250. PMID: 28054395, PMCID: PMC6143144, DOI: 10.1111/acer.13291.Peer-Reviewed Original ResearchConceptsAlcohol inhalationAlcohol consumptionAcute alcohol exposureElevated blood alcohol concentrationsRoute of administrationOral alcohol consumptionFirst-pass metabolismAlcohol use disorderPublic health concernMeasurement of biomarkersBlood alcohol concentrationRisk of addictionPharmacodynamic profileAlcohol exposureArterial circulationOccupational exposureMeasurable biomarkersPharmacological effectsUse disordersInhalationE-cigarettesHealth concernSubjective effectsRisk of problemsGoogle Scholar
2016
Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries
Garay R, Citrome L, Samalin L, Liu C, Thomsen M, Correll C, Hameg A, Llorca P. Therapeutic improvements expected in the near future for schizophrenia and schizoaffective disorder: an appraisal of phase III clinical trials of schizophrenia-targeted therapies as found in US and EU clinical trial registries. Expert Opinion On Pharmacotherapy 2016, 17: 921-936. PMID: 26831200, DOI: 10.1517/14656566.2016.1149164.Peer-Reviewed Original ResearchConceptsCognitive impairment associated with schizophreniaSchizoaffective disorderNegative symptomsDopamine D2 receptor partial agonistTreatment of cognitive impairment associated with schizophreniaD2 receptor partial agonistTreating positive symptomsReceptor partial agonistEU clinical trial registriesAdd-on compoundsTardive dyskinesiaPositive symptomsGoal of recoverySchizophreniaPartial agonistAntipsychoticsSchizoaffectivePhase III of clinical developmentTherapeutic improvementDisordersClinical Trials RegistrySymptomsPharmacodynamic profileClinical developmentAcademic medical center
2015
The past, present, and future of basal insulins
Pettus J, Santos Cavaiola T, Tamborlane WV, Edelman S. The past, present, and future of basal insulins. Diabetes/Metabolism Research And Reviews 2015, 32: 478-496. PMID: 26509843, DOI: 10.1002/dmrr.2763.Peer-Reviewed Original ResearchConceptsInsulin glargine 100Basal insulinGlargine 100Glycemic controlUnits/mLNew insulin glargine 300Neutral protamine Hagedorn (NPH) insulinBasal insulin peglisproNew insulin productsSimilar glycemic controlGood glycemic controlInsulin glargine 300Type 2 diabetesDuration of actionInsulin delivery techniquesGlargine 300Insulin detemirInsulin therapyInsulin degludecNew insulinsPharmacodynamic profileInsulin secretionPharmacodynamic propertiesPrandial increaseFundamental therapyEffects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice
Jackson KJ, Jackson A, Carroll FI, Damaj MI. Effects of orally-bioavailable short-acting kappa opioid receptor-selective antagonist LY2456302 on nicotine withdrawal in mice. Neuropharmacology 2015, 97: 270-274. PMID: 26044637, PMCID: PMC4537361, DOI: 10.1016/j.neuropharm.2015.05.023.Peer-Reviewed Original ResearchConceptsNicotine withdrawal syndromeWithdrawal syndromeKOR antagonistsAnxiety-related behaviorNicotine withdrawalSomatic signsKappa Opioid Receptor SignalingSelective KOR antagonistAffective nicotine withdrawal signsNicotine withdrawal signsOpioid receptor signalingUseful therapeutic agentShort actingHotplate latencyWithdrawal signsPharmacodynamic profileClinical studiesMood disordersLY2456302Animal modelsPlace aversionDrug dependenceTherapeutic potentialDecreased expressionAntagonist
2012
Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device
Cengiz E, Weinzimer SA, Sherr JL, Tichy E, Martin M, Carria L, Steffen A, Tamborlane WV. Acceleration of insulin pharmacodynamic profile by a novel insulin infusion site warming device. Pediatric Diabetes 2012, 14: 168-173. PMID: 23107353, PMCID: PMC3572265, DOI: 10.1111/pedi.12001.Peer-Reviewed Original ResearchConceptsPlasma insulin levelsInsulin actionInsulin levelsAspart insulinRapid-acting insulin analoguesPhysiologic insulin actionClosed-loop insulin deliveryPostprandial glucose excursionsEuglycemic clamp techniqueIp activationTime-action profileType 1 diabetesWarming devicesEuglycemic clamp procedureBolus doseGlucose excursionsPharmacodynamic profileClamp procedurePeak actionInfusion siteBlood flowInsulin analoguesClamp techniqueInsulin absorptionInsulin bolus
1997
The Expanding Indications for Clozapine
Young C, Longhurst J, Bowers M, Mazure C. The Expanding Indications for Clozapine. Experimental And Clinical Psychopharmacology 1997, 5: 216-234. PMID: 9260069, DOI: 10.1037/1064-1297.5.3.216.Peer-Reviewed Original ResearchConceptsUnique pharmacodynamic profileUse of clozapineTreatment-resistant schizophreniaTraditional drug treatmentExpanding IndicationsClozapine treatmentNeurologic conditionsPharmacodynamic profileClinical indicationsDrug treatmentMood disordersEffective treatmentClozapineSubstance abuseChildhood schizophreniaRelevant literatureSchizophreniaDisordersTreatmentAggressive behaviorIndicationsInitial rationaleAgranulocytosisPatientsBody of literature
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply